ExpreS2ion Biotech Holding AB (publ)
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalo… Read more
ExpreS2ion Biotech Holding AB (publ) (5JD0) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.314x
Based on the latest financial reports, ExpreS2ion Biotech Holding AB (publ) (5JD0) has a cash flow conversion efficiency ratio of -0.314x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.46 Million) by net assets (€33.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ExpreS2ion Biotech Holding AB (publ) - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how ExpreS2ion Biotech Holding AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ExpreS2ion Biotech Holding AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ExpreS2ion Biotech Holding AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trenchant Technologies Capital Corp.
PINK:AITTF
|
-0.049x |
|
ABERCROMBIE FTCH-A
BE:AFT
|
0.135x |
|
Meiwu Technology Co Ltd
NASDAQ:WNW
|
0.115x |
|
Immolease Trust NV
BR:DIEG
|
N/A |
|
Evofem Biosciences Inc
OTCQB:EVFM
|
0.034x |
|
Cleantech Power Corp.
PINK:PWWRF
|
-0.220x |
|
Nuzee Inc
NASDAQ:NUZE
|
4.967x |
|
Cascadero Copper Corporation
PINK:CCEDF
|
0.168x |
Annual Cash Flow Conversion Efficiency for ExpreS2ion Biotech Holding AB (publ) (2021–2024)
The table below shows the annual cash flow conversion efficiency of ExpreS2ion Biotech Holding AB (publ) from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €64.80 Million | €-33.93 Million | -0.524x | +66.08% |
| 2023-12-31 | €65.36 Million | €-100.89 Million | -1.543x | -60.10% |
| 2022-12-31 | €103.33 Million | €-99.61 Million | -0.964x | -196.42% |
| 2021-12-31 | €140.35 Million | €-45.65 Million | -0.325x | -- |